PHVS Fundamental Analysis - PHARVARIS NV

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to PHVS. PHVS was compared to 193 industry peers in the Pharmaceuticals industry. PHVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHVS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

PHVS had negative earnings in the past year.

PHVS had a negative operating cash flow in the past year.

PHVS had negative earnings in each of the past 5 years.

PHVS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

PHVS has a worse Return On Assets (-61.49%) than 64.25% of its industry peers.

Looking at the Return On Equity, with a value of -67.70%, PHVS is in line with its industry, outperforming 48.19% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-61.49%
ROE	-67.7%
ROIC	N/A

ROA(3y)-38.96%

ROA(5y)-32.55%

ROE(3y)-42.51%

ROE(5y)-35.1%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PHVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, PHVS has more shares outstanding

The number of shares outstanding for PHVS has been increased compared to 5 years ago.

PHVS has a worse debt/assets ratio than last year.

2.2 Solvency

PHVS has an Altman-Z score of 27.62. This indicates that PHVS is financially healthy and has little risk of bankruptcy at the moment.

PHVS's Altman-Z score of 27.62 is amongst the best of the industry. PHVS outperforms 94.82% of its industry peers.

PHVS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of PHVS (0.00) is better than 61.14% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	27.62

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 11.10 indicates that PHVS has no problem at all paying its short term obligations.

PHVS has a better Current ratio (11.10) than 84.46% of its industry peers.

A Quick Ratio of 11.10 indicates that PHVS has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 11.10, PHVS belongs to the top of the industry, outperforming 84.46% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	11.1
Quick Ratio	11.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for PHVS have decreased strongly by -28.22% in the last year.

EPS 1Y (TTM)-28.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-50.91%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PHVS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.05% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-25.95%

EPS Next 2Y-12.83%

EPS Next 3Y1.14%

EPS Next 5Y20.05%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PHVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PHVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-12.83%

EPS Next 3Y1.14%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PHVS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PHARVARIS NV

NASDAQ:PHVS (8/14/2025, 12:49:24 PM)

21.19

-0.24 (-1.12%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-12 2025-08-12/amc

Earnings (Next)11-11 2025-11-11/amc

Inst Owners50.44%

Inst Owner Change0.1%

Ins Owners5.32%

Ins Owner ChangeN/A

Market Cap1.36B

Analysts85.88

Price Target33.47 (57.95%)

Short Float %2.37%

Short Ratio7.54

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)1.9%

Min EPS beat(2)-9.19%

Max EPS beat(2)12.99%

EPS beat(4)2

Avg EPS beat(4)-4.34%

Min EPS beat(4)-23.64%

Max EPS beat(4)12.99%

EPS beat(8)5

Avg EPS beat(8)-4.66%

EPS beat(12)8

Avg EPS beat(12)-0.6%

EPS beat(16)11

Avg EPS beat(16)-2.65%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.82%

PT rev (3m)-3.12%

EPS NQ rev (1m)0%

EPS NQ rev (3m)7.65%

EPS NY rev (1m)0%

EPS NY rev (3m)8.14%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	5.14
P/tB	5.14
EV/EBITDA	N/A

EPS(TTM)-3.62

EYN/A

EPS(NY)-3.7

Fwd EYN/A

FCF(TTM)-2.47

FCFYN/A

OCF(TTM)-2.46

OCFYN/A

SpS0

BVpS4.12

TBVpS4.12

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-61.49%
ROE	-67.7%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-38.96%

ROA(5y)-32.55%

ROE(3y)-42.51%

ROE(5y)-35.1%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	216.66%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	11.1
Quick Ratio	11.1
Altman-Z	27.62

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)104.84%

Cap/Depr(5y)175.41%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-28.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-50.91%

EPS Next Y-25.95%

EPS Next 2Y-12.83%

EPS Next 3Y1.14%

EPS Next 5Y20.05%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-53.2%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-25.55%

EBIT Next 3Y-4.98%

EBIT Next 5YN/A

FCF growth 1Y-81.04%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-80.41%

OCF growth 3YN/A

OCF growth 5YN/A

PHARVARIS NV (PHVS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens